Armata Pharmaceuticals Stock Analysis
| ARMP Stock | USD 8.03 0.21 2.55% |
IPO Date 9th of March 2011 | 200 Day MA 3.9003 | 50 Day MA 6.4678 | Beta 1.421 |
Armata Pharmaceuticals holds a debt-to-equity ratio of 0.73. At this time, Armata Pharmaceuticals' Total Debt To Capitalization is relatively stable compared to the past year. As of 02/13/2026, Debt Ratio is likely to grow to 1.38, while Interest Debt Per Share is likely to drop 4.15. Armata Pharmaceuticals' financial risk is the risk to Armata Pharmaceuticals stockholders that is caused by an increase in debt.
Asset vs Debt
Equity vs Debt
Armata Pharmaceuticals' liquidity is one of the most fundamental aspects of both its future profitability and its ability to meet different types of ongoing financial obligations. Armata Pharmaceuticals' cash, liquid assets, total liabilities, and shareholder equity can be utilized to evaluate how much leverage the Company is using to sustain its current operations. For traders, higher-leverage indicators usually imply a higher risk to shareholders. In addition, it helps Armata Stock's retail investors understand whether an upcoming fall or rise in the market will negatively affect Armata Pharmaceuticals' stakeholders.
For many companies, including Armata Pharmaceuticals, marketable securities, inventories, and receivables are the most common assets that could be converted to cash. However, for Armata Pharmaceuticals, the most critical issue when managing liquidity is ensuring that current assets are properly aligned with current liabilities. If they are not, Armata Pharmaceuticals' management will need to obtain alternative financing to ensure there are always enough cash equivalents on the balance sheet to meet obligations.
Price Book 2.1095 | Enterprise Value Ebitda 15.7239 | Price Sales 57.6287 | Shares Float 11 M | Wall Street Target Price 12 |
Given that Armata Pharmaceuticals' debt-to-equity ratio measures a Company's obligations relative to the value of its net assets, it is usually used by traders to estimate the extent to which Armata Pharmaceuticals is acquiring new debt as a mechanism of leveraging its assets. A high debt-to-equity ratio is generally associated with increased risk, implying that it has been aggressive in financing its growth with debt. Another way to look at debt-to-equity ratios is to compare the overall debt load of Armata Pharmaceuticals to its assets or equity, showing how much of the company assets belong to shareholders vs. creditors. If shareholders own more assets, Armata Pharmaceuticals is said to be less leveraged. If creditors hold a majority of Armata Pharmaceuticals' assets, the Company is said to be highly leveraged.
At this time, Armata Pharmaceuticals' Common Stock Shares Outstanding is relatively stable compared to the past year. As of 02/13/2026, Liabilities And Stockholders Equity is likely to grow to about 104.4 M, though Total Stockholder Equity is likely to grow to (41.1 M). . As of 02/13/2026, Price To Sales Ratio is likely to drop to 14.13. In addition to that, Price Earnings Ratio is likely to drop to -3.34. Armata Pharmaceuticals is undervalued with Real Value of 9.17 and Target Price of 12.0. The main objective of Armata Pharmaceuticals stock analysis is to determine its intrinsic value, which is an estimate of what Armata Pharmaceuticals is worth, separate from its market price. There are two main types of Armata Pharmaceuticals' stock analysis: fundamental analysis and technical analysis.
The Armata Pharmaceuticals stock is traded in the USA on NYSE MKT Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Armata Pharmaceuticals is usually not traded on Labour Day, Thanksgiving Day, Christmas Day, New Year 's Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day, Juneteenth Holiday, Independence Day ( substitute day ), Independence Day. Armata Stock trading window is adjusted to America/New York timezone.
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Armata Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. Armata Stock Analysis Notes
About 69.0% of the company shares are held by company insiders. The company recorded a loss per share of 1.66. Armata Pharmaceuticals last dividend was issued on the 10th of May 2019. The entity had 1:14 split on the 10th of May 2019. Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It has a partnership agreement with Merck Co. for developing synthetic bacteriophage candidates to target undisclosed infectious disease agents. Armata Pharmaceuticals operates under Biotechnology classification in the United States and is traded on AMEX Exchange. It employs 69 people. For more info on Armata Pharmaceuticals please contact Deborah MD at 310 665 2928 or go to https://www.armatapharma.com.Armata Pharmaceuticals Investment Alerts
| Armata Pharmaceuticals is way too risky over 90 days horizon | |
| Armata Pharmaceuticals appears to be risky and price may revert if volatility continues | |
| Armata Pharmaceuticals has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 5.17 M. Net Loss for the year was (18.92 M) with loss before overhead, payroll, taxes, and interest of (21.04 M). | |
| Armata Pharmaceuticals currently holds about 36.98 M in cash with (37.55 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.02. | |
| Armata Pharmaceuticals has a very weak financial position based on the latest SEC disclosures | |
| Roughly 69.0% of the company shares are held by company insiders | |
| Latest headline from news.google.com: Armata Pharmaceuticals, Inc. Short Interest Update - MarketBeat |
Armata Largest EPS Surprises
Earnings surprises can significantly impact Armata Pharmaceuticals' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2022-08-11 | 2022-06-30 | -0.23 | -0.26 | -0.03 | 13 | ||
2022-11-09 | 2022-09-30 | -0.28 | -0.24 | 0.04 | 14 | ||
2021-11-10 | 2021-09-30 | -0.26 | -0.22 | 0.04 | 15 |
Armata Pharmaceuticals Environmental, Social, and Governance (ESG) Scores
Armata Pharmaceuticals' ESG score is a quantitative measure that evaluates Armata Pharmaceuticals' performance and commitment regarding environmental, social, and governance (ESG) factors. These scores are becoming increasingly crucial in investment decision-making processes, providing insights into non-financial aspects of Armata Pharmaceuticals' operations that may have significant financial implications and affect Armata Pharmaceuticals' stock price as well as guide investors towards more socially responsible investments.
Armata Market Capitalization
The company currently falls under 'Small-Cap' category with a current market capitalization of 291.26 M.Armata Profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.23) | (0.25) | |
| Return On Capital Employed | (1.28) | (1.34) | |
| Return On Assets | (0.20) | (0.21) | |
| Return On Equity | 0.35 | 0.37 |
Management Efficiency
Armata Pharmaceuticals has return on total asset (ROA) of (0.222) % which means that it has lost $0.222 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (34.3935) %, meaning that it created substantial loss on money invested by shareholders. Armata Pharmaceuticals' management efficiency ratios could be used to measure how well Armata Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. As of 02/13/2026, Return On Equity is likely to grow to 0.37, while Return On Tangible Assets are likely to drop (0.25). As of 02/13/2026, Total Current Liabilities is likely to grow to about 58.3 M. Also, Liabilities And Stockholders Equity is likely to grow to about 104.4 M| Last Reported | Projected for Next Year | ||
| Book Value Per Share | (1.53) | (1.45) | |
| Tangible Book Value Per Share | (1.96) | (1.87) | |
| Enterprise Value Over EBITDA | (4.03) | (4.23) | |
| Price Book Value Ratio | (1.60) | (1.52) | |
| Enterprise Value Multiple | (4.03) | (4.23) | |
| Price Fair Value | (1.60) | (1.52) | |
| Enterprise Value | 165.7 M | 174 M |
Armata Pharmaceuticals has shown resilience through effective management strategies. Our analysis examines how these strategies influence financial outcomes and investor returns which helps in understanding the stock's long-term potential.
Technical Drivers
As of the 13th of February 2026, Armata Pharmaceuticals shows the Mean Deviation of 5.19, risk adjusted performance of 0.099, and Downside Deviation of 6.55. Armata Pharmaceuticals technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.Armata Pharmaceuticals Price Movement Analysis
Illegal number of arguments. The output start index for this execution was zero with a total number of output elements of zero. The Weighted Moving Average calculates a weight for each value in Armata Pharmaceuticals price series with the more recent values given greater weights.
Armata Pharmaceuticals Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Armata Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Armata Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Armata Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Armata Pharmaceuticals Outstanding Bonds
Armata Pharmaceuticals issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Armata Pharmaceuticals uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Armata bonds can be classified according to their maturity, which is the date when Armata Pharmaceuticals has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
Armata Pharmaceuticals Predictive Daily Indicators
Armata Pharmaceuticals intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Armata Pharmaceuticals stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Rate Of Daily Change | 0.97 | |||
| Day Median Price | 8.03 | |||
| Day Typical Price | 8.03 | |||
| Price Action Indicator | (0.11) | |||
| Period Momentum Indicator | (0.21) |
Armata Pharmaceuticals Corporate Filings
8K | 26th of January 2026 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
8K | 13th of January 2026 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
| 1st of December 2025 Other Reports | ViewVerify | |
8K | 12th of November 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
8K | 22nd of October 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
8K | 11th of September 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
| 25th of August 2025 Other Reports | ViewVerify | |
| 13th of August 2025 Other Reports | ViewVerify |
Armata Pharmaceuticals Forecast Models
Armata Pharmaceuticals' time-series forecasting models are one of many Armata Pharmaceuticals' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Armata Pharmaceuticals' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.Armata Pharmaceuticals Bond Ratings
Armata Pharmaceuticals financial ratings play a critical role in determining how much Armata Pharmaceuticals have to pay to access credit markets, i.e., the amount of interest on their issued debt. The threshold between investment-grade and speculative-grade ratings has important market implications for Armata Pharmaceuticals' borrowing costs.| Piotroski F Score | 1 | Very Weak | View |
| Beneish M Score | (2.23) | Unlikely Manipulator | View |
Armata Pharmaceuticals Debt to Cash Allocation
Armata Pharmaceuticals currently holds 126.52 M in liabilities with Debt to Equity (D/E) ratio of 0.73, which is about average as compared to similar companies. Armata Pharmaceuticals has a current ratio of 5.48, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Armata Pharmaceuticals' use of debt, we should always consider it together with its cash and equity.Armata Pharmaceuticals Total Assets Over Time
Armata Pharmaceuticals Assets Financed by Debt
The debt-to-assets ratio shows the degree to which Armata Pharmaceuticals uses debt to finance its assets. It includes both long-term and short-term borrowings maturing within one year. It also includes both tangible and intangible assets, such as goodwill.Armata Pharmaceuticals Debt Ratio | 138.0 |
Armata Pharmaceuticals Corporate Bonds Issued
Armata Short Long Term Debt Total
Short Long Term Debt Total |
|
About Armata Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how Armata Pharmaceuticals prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Armata shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Armata Pharmaceuticals. By using and applying Armata Stock analysis, traders can create a robust methodology for identifying Armata entry and exit points for their positions.
| Last Reported | Projected for Next Year | ||
| Pretax Profit Margin | (4.20) | (4.41) | |
| Operating Profit Margin | (9.43) | (9.90) | |
| Net Loss | (4.20) | (4.41) | |
| Gross Profit Margin | (6.50) | (6.18) |
Current Armata Analysis - Recommendations
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Armata analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Armata analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
| Target Price | Consensus | # of Analysts | |
| 12.0 | Buy | 1 | Odds |
Most Armata analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Armata stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Armata Pharmaceuticals, talking to its executives and customers, or listening to Armata conference calls.
Armata Stock Analysis Indicators
Armata Pharmaceuticals stock analysis indicators help investors evaluate how Armata Pharmaceuticals stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Armata Pharmaceuticals shares will generate the highest return on investment. By understating and applying Armata Pharmaceuticals stock analysis, traders can identify Armata Pharmaceuticals position entry and exit signals to maximize returns.
| Begin Period Cash Flow | 19.2 M | |
| Long Term Debt | 55.4 M | |
| Common Stock Shares Outstanding | 36.2 M | |
| Total Stockholder Equity | -48 M | |
| Total Cashflows From Investing Activities | -1.9 M | |
| Property Plant And Equipment Net | 54.9 M | |
| Cash And Short Term Investments | 9.3 M | |
| Cash | 9.3 M | |
| Accounts Payable | 766 K | |
| Net Debt | 117.2 M | |
| 50 Day M A | 6.4678 | |
| Total Current Liabilities | 48.2 M | |
| Other Operating Expenses | 47.6 M | |
| Non Current Assets Total | 75.1 M | |
| Non Currrent Assets Other | 975 K | |
| Stock Based Compensation | 2.9 M |
Additional Tools for Armata Stock Analysis
When running Armata Pharmaceuticals' price analysis, check to measure Armata Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Armata Pharmaceuticals is operating at the current time. Most of Armata Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Armata Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Armata Pharmaceuticals' price. Additionally, you may evaluate how the addition of Armata Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.